Y-mAbs Therapeutics Inc. (YMAB)
$8.61
$0.00 (0.00%)As on 16-Sep-2025 09:30EDT
Market cap
$391 Mln
Revenue (TTM)
$85 Mln
P/E Ratio
--
P/B Ratio
4.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
45,438,400
8 Years Aggregate
CFO
$-438.70 Mln
EBITDA
$-509.13 Mln
Net Profit
$-450.82 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Y-mAbs Therapeutics (YMAB)
| 10.0 | 1.1 | 82.8 | -37.3 | -15.9 | -26.2 | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Y-mAbs Therapeutics (YMAB)
| 14.7 | 39.8 | -69.9 | -67.3 | 58.4 | 53.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Y-mAbs Therapeutics (YMAB)
|
8.6 | 391.2 | 85.4 | -22.2 | -24.7 | -24.8 | -- | 4.5 |
| 2.1 | 104.8 | 0.0 | -71.1 | -- | -47 | -- | 0.7 |
Shareholding Pattern
View DetailsAbout Y-mAbs Therapeutics (YMAB)
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal... antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. As of September 15, 2025, Y-mAbs Therapeutics, Inc. operates as a subsidiary of SERB S.A.S. Read more
-
Founder, Chief Business Officer & Vice Chairman
Mr. Thomas Gad
-
Founder, Chief Business Officer & Vice Chairman
Mr. Thomas Gad
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Y-mAbs Therapeutics (YMAB)
What is the current share price of Y-mAbs Therapeutics Inc (YMAB) Today?
The share price of Y-mAbs Therapeutics Inc (YMAB) is $8.61 (NASDAQ) as of 16-Sep-2025 09:30 EDT. Y-mAbs Therapeutics Inc (YMAB) has given a return of -15.95% in the last 3 years.
What is the current PB & PE ratio of Y-mAbs Therapeutics Inc (YMAB)?
Since, TTM earnings of Y-mAbs Therapeutics Inc (YMAB) is negative, P/E ratio is not available.
The P/B ratio of Y-mAbs Therapeutics Inc (YMAB) is 4.47 times as on 16-Sep-2025, a 14 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-11.84 |
3.82 |
2023 |
-13.89 |
2.95 |
2022 |
-2.26 |
2.00 |
2021 |
-12.54 |
3.92 |
2020 |
-18.41 |
20.76 |
What is the 52 Week High and Low of Y-mAbs Therapeutics Inc (YMAB)?
The 52-week high and low of Y-mAbs Therapeutics Inc (YMAB) are Rs 16.10 and Rs 3.55 as of 02-Sep-2026.
What is the market cap of Y-mAbs Therapeutics Inc (YMAB)?
Y-mAbs Therapeutics Inc (YMAB) has a market capitalisation of $ 391 Mln as on 16-Sep-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Y-mAbs Therapeutics Inc (YMAB)?
Before investing in Y-mAbs Therapeutics Inc (YMAB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.